E-viri
Recenzirano
-
Shin, Daniel Sanghoon; Ribas, Antoni
Current opinion in immunology, 04/2015, Letnik: 33Journal Article
Highlights • First FDA approvals for anti-PD-1 antibodies for patients with metastatic melanoma. • Promising response from ongoing clinical trials with several anti-PD-1/L1 antibodies. • Need to define bio-markers to predict response from anti-PD-1/L1 antibody therapy. • Multiple checkpoint inhibitors that are under pre-clinical development. • Future studies will identify ideal combinations of checkpoint inhibitors.
